Esculetin inhibits the PI3K/Akt/mTOR pathway and enhances anti-colorectal cancer activity via binding to ENO1.

ABSTRACT:

Introduction

Colorectal cancer (CRC) ranks as the third most prevalent malignant tumor worldwide and is the second leading cause of cancer-related mortality. At present, while its standard treatment consists of a combination of surgery and chemotherapy, metastasis and recurrence are generally associated with a poor prognosis.

Methods

Flow cytometry with Hoechst 33342 staining was employed to detect the changes in cell cycle and apoptosis in CRC cells. The molecular mechanisms of Esc's antitumor properties were elucidated through network pharmacology, transcriptome sequencing technology, drug affinity responsive target stability (DARTS), and molecular docking. The in vivo antitumor effects of Esc were examined using the xenograft mouse model.

Results

In this stu

SUBMITTER: Ma J 

PROVIDER: S-EPMC12307286 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature